Drug
D0140 | Anisomycin
| Pictogram | Signal | Statements | Precautionary Statement Codes |
|---|---|---|---|
 |
Danger |
Aggregated GHS information provided by 62 companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. H301 (98.39%): Toxic if swallowed [Danger Acute toxicity, oral] H311 (29.03%): Toxic in contact with skin [Danger Acute toxicity, dermal] H331 (27.42%): Toxic if inhaled [Danger Acute toxicity, inhalation] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P261, P264, P270, P271, P280, P301+P310, P302+P352, P304+P340, P311, P312, P321, P322, P330, P361, P363, P403+P233, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| Organism | Test type | Route | Dose (normalized dose) | Effect | Source |
|---|---|---|---|---|---|
| rat | LD50 | intraperitoneal | 345mg/kg (345mg/kg) | Antibiotics and Chemotherapy Vol. 5, Pg. 490, 1955. | |
| rabbit | LD | oral | > 200mg/kg (200mg/kg) | Antibiotics and Chemotherapy Vol. 5, Pg. 490, 1955. | |
| mouse | LD50 | subcutaneous | 600mg/kg (600mg/kg) | Antibiotics and Chemotherapy Vol. 5, Pg. 490, 1955. | |
| guinea pig | LDLo | oral | 300mg/kg (300mg/kg) | Antibiotics and Chemotherapy Vol. 5, Pg. 490, 1955. | |
| dog | LD | intravenous | > 100mg/kg (100mg/kg) | gastrointestinal: nausea or vomiting | Antibiotics and Chemotherapy Vol. 5, Pg. 490, 1955. |
| mouse | LD50 | intraperitoneal | 400mg/kg (400mg/kg) | Antibiotics and Chemotherapy Vol. 5, Pg. 490, 1955. | |
| mouse | LD50 | intravenous | 10mg/kg (10mg/kg) | "CRC Handbook of Antibiotic Compounds," Vols.1- , Berdy, J., Boca Raton, FL, CRC Press, 1980Vol. 5, Pg. 77, 1981. | |
| rat | LD50 | oral | 72mg/kg (72mg/kg) | Antibiotics and Chemotherapy Vol. 5, Pg. 490, 1955. | |
| monkey | LDLo | intravenous | 200mg/kg (200mg/kg) | gastrointestinal: nausea or vomiting | Antibiotics and Chemotherapy Vol. 5, Pg. 490, 1955. |
| dog | LD | intramuscular | > 100mg/kg (100mg/kg) | gastrointestinal: nausea or vomiting | Antibiotics and Chemotherapy Vol. 5, Pg. 490, 1955. |
| monkey | LD | oral | > 300mg/kg (300mg/kg) | gastrointestinal: nausea or vomiting | Antibiotics and Chemotherapy Vol. 5, Pg. 490, 1955. |
| rat | LD50 | subcutaneous | 230mg/kg (230mg/kg) | Antibiotics and Chemotherapy Vol. 5, Pg. 490, 1955. | |
| monkey | LD | intramuscular | > 50mg/kg (50mg/kg) | gastrointestinal: nausea or vomiting | Antibiotics and Chemotherapy Vol. 5, Pg. 490, 1955. |
| mouse | LD50 | oral | 148mg/kg (148mg/kg) | Antibiotics and Chemotherapy Vol. 5, Pg. 490, 1955. | |
| dog | LD | oral | > 300mg/kg (300mg/kg) | gastrointestinal: nausea or vomiting | Antibiotics and Chemotherapy Vol. 5, Pg. 490, 1955. |
| rat | LD50 | intravenous | 167mg/kg (167mg/kg) | Antibiotics and Chemotherapy Vol. 5, Pg. 490, 1955. | |
| cat | LD | oral | > 200mg/kg (200mg/kg) | gastrointestinal: nausea or vomiting | Antibiotics and Chemotherapy Vol. 5, Pg. 490, 1955. |
| (-) Anisomycin | (-)-Anisomycin | (2R,3S,4S)-2-((4-Methoxyphenyl)methyl)-3,4-pyrrolidinediol 3-acetate |
| (2R,3S,4S)-2-(4-Methoxybenzyl)-3,4-pyrrolidinediol 3-Acetate | (2R,3S,4S)-2-(4-Methoxybenzyl)-3,4-pyrrolidinediol-3-acetate | (2R,3S,4S)-2-(p-Methoxybenzyl)-3,4-pyrrolidinediol 3-acetate |
| (2R,3S,4S)-2-(p-Methoxyphenylmethyl)-3-acetoxy-4-hydroxypyrrolidine | (2R,3S,4S)-2-[(4-Methoxyphenyl)methyl]-3,4-pyrrolidinediol 3-acetate | (2R,3S,4S)-4-hydroxy-2-(4-methoxybenzyl)pyrrolidin-3-yl acetate |
| (2R,3S,4S)-4-hydroxy-2-[(4-methoxyphenyl)methyl]pyrrolidin-3-yl acetate | 1,4,5-Trideoxy-1,4-imino-5-(p-methoxyphenyl)-D-xylo-pentitol 3-acetate | 2-(p-Methoxybenzyl)-3,4-pyrrolidinediol 3-acetate |
| 2-(p-Methoxybenzyl)-3,4-pyrrolidinediol-3-acetate | 2-[(4-Methoxyphenyl)methyl]-3,4-pyrrolidinediol 3-acetate | 2-p-Methoxyphenylmethyl-3-acetoxy-4-hydroxypyrrolidine |
| 22862-76-6 | 3, 2-(p-methoxybenzyl)-, 3-acetate, (2S,3R,4R)- | 3, 2-[(4-methoxyphenyl)methyl]-, 3-acetate, [2S-(2.alpha.,3.alpha.,4.beta.)]- |
| 3,4-Pyrrolidinediol, 2-((4-methoxyphenyl)methyl)-, 3-acetate, (2R,3S,4S)- | 3,4-Pyrrolidinediol, 2-((4-methoxyphenyl)methyl)-, 3-acetate, (2R-(2-alpha,3-alpha,4-beta))- | 3,4-Pyrrolidinediol, 2-((4-methoxyphenyl)methyl)-, 3-acetate, (2R-(2alpha,3alpha,4beta))- |
| 3,4-Pyrrolidinediol, 2-(p-methoxybenzyl)-, 3-acetate, (2S,3R,4R)- | 3,4-Pyrrolidinediol, 2-(p-methoxybenzyl)-, 3-acetate, (2S,3R,4R)- (8CI) | 3,4-Pyrrolidinediol, 2-[(4-methoxyphenyl)methyl]-, 3-acetate, (2R,3S,4S)- |
| 5-21-05-00523 (Beilstein Handbook Reference) | 6185-RBK-10 | 6C74YM2NGI |
| AB00513833 | AI3-50846 | AKOS015916532 |
| ANM | API0001506 | AS-44380 |
| Anisomycin from Streptomyces griseolus | Anisomycin from Streptomyces griseolus, >=98% (HPLC), solid | Anisomycin, Antibiotic for Culture Media Use Only |
| Anisomycin, Streptomyces griseolus | Anisomycin,streptomyces griseolus | Antibiotic PA-106 |
| B6674 | BDBM63919 | BIA4315 |
| BPBio1_000402 | BRD-K91370081-001-04-6 | BRD-K91370081-001-17-8 |
| BRN 0020705 | BS0234 | BSPBio_000364 |
| BSPBio_001436 | Bio1_000350 | Bio1_000839 |
| Bio1_001328 | C11281 | C14H19NO4 |
| CBiol_002064 | CCG-39185 | CHEBI:338412 |
| CHEMBL423192 | CS-4981 | DB07374 |
| DTXSID5040966 | DivK1c_000855 | EBD11190 |
| EINECS 245-269-7 | Flagecidin | GA2328 |
| GNF-Pf-4549 | HMS1922K06 | HMS2096C06 |
| HMS2231E05 | HMS3267L11 | HMS3414L17 |
| HMS3678L15 | HMS502K17 | HY-18982 |
| IDI1_000855 | KBio1_000855 | KBio2_002014 |
| KBio2_004582 | KBio2_007150 | KBioGR_001076 |
| KBioSS_002014 | KS-0000001J | MFCD00077650 |
| MLS001066392 | NCGC00025097-02 | NCGC00025097-03 |
| NCGC00025097-04 | NCI60_041689 | NINDS_000855 |
| NSC 76712 | NSC-76712 | NSC76712 |
| Prestwick3_000412 | Q378498 | QTL1_000009 |
| SCHEMBL2270183 | SDCCGMLS-0066810.P001 | SMR000471874 |
| SPBio_000624 | SPECTRUM1503906 | SR-01000597397 |
| SR-01000597397-1 | SR-01000597397-3 | Spectrum2_000632 |
| Spectrum4_000748 | Spectrum5_001495 | Spectrum_001534 |
| TCMDC-125504 | UNII-6C74YM2NGI | Upjohn 204t3 |
| Wuningmeisu C | YKJYKKNCCRKFSL-RDBSUJKOSA-N | ZINC954 |
| ZX-AFC000035 | [(2R,3S,4S)-2-[(4-methoxyphenyl)methyl]-4-oxidanyl-pyrrolidin-3-yl] ethanoate | [(2R,3S,4S)-4-hydroxy-2-[(4-methoxyphenyl)methyl]pyrrolidin-3-yl] acetate |
| acetic acid [(2R,3S,4S)-4-hydroxy-2-[(4-methoxyphenyl)methyl]-3-pyrrolidinyl] ester | acetic acid [(2R,3S,4S)-4-hydroxy-2-p-anisyl-pyrrolidin-3-yl] ester | anisomycin |
| cid_253602 |
| DrugBank Name | Anisomycin |
| DrugBank | DB07374 |
| CAS Number | 11023-48-6, 22862-76-6, 25940-57-2 |
| PubChem Compound | 253602 |
| KEGG Compound ID | C11281 |
| PubChem.Substance | 99443845 |
| ChEBI | 338412 |
| ChemSpider | 222267 |
| BindingDB | 63919.0 |
| Wikipedia | Anisomycin |
| HET | ANM |